Treprostinil

Generic Name: Treprostinil

Brand Names: Orenitram, Remodulin, Tyvaso, Trepulmix

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₃₄O_₅

CAS Number: 81846-19-7

Unique Ingredient Identifier: RUM6K67ESG

Background: Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation. It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease. The first agent approved for th...

Indication: The FDA has indicated treprostinil for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to improve exercise ability. It is also used to treat pulmonary arterial hypertension in patients requiring transition from epoprostenol. The Health Canada label specifies that treprostinil is indicated ...

Associated Conditions: Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH)

Associated Therapies: -

Clinical Trials

Acute Effects of Inhaled Treprostinil in Fontan Patients

Phase 2

Terminated

Conditions: Congenital Heart Disease

Interventions: Drug: Placebo
Drug: Treprostinil

First Posted Date: 2016-05-11

Last Posted Date: 2020-07-29

Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Target Recruit Count: 15

Registration Number: NCT02769624

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation

Not Applicable

Terminated

Conditions: Single Ventricle

Interventions: Drug: Treprostinil

First Posted Date: 2015-07-15

Last Posted Date: 2022-03-31

Lead Sponsor: Stanford University

Target Recruit Count: 34

Registration Number: NCT02498444

Locations: 🇺🇸
Lucile Packard Children's Hospital, Stanford, Palo Alto, California, United States

Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension

Not Applicable

Withdrawn

Conditions: Congenital Heart Disease

Interventions: Drug: Remodulin

First Posted Date: 2013-11-11

Last Posted Date: 2017-09-21

Lead Sponsor: University of California, Los Angeles

Registration Number: NCT01980979

Locations: 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸
Ohio State University/Nationwide Children's Hospital, Columbus, Ohio, United States

Safety and Efficacy of Treprostinil in Ischemia and Reperfusion Injury in Adult Orthotopic Liver Transplantation

Phase 1

Completed

Conditions: Ischemia Reperfusion Injury

Interventions: Drug: Treprostinil

First Posted Date: 2011-11-30

Last Posted Date: 2023-12-15

Lead Sponsor: Abhinav Humar, MD

Target Recruit Count: 35

Registration Number: NCT01481974

Locations: 🇺🇸
Abhinav Humar, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication

Phase 4

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Treprostinil

First Posted Date: 2010-12-31

Last Posted Date: 2017-09-01

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 6

Registration Number: NCT01268553

Locations: 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸
University of CA, San Francisco, San Francisco, California, United States
🇺🇸
University of Arizona, Tucson, Arizona, United States

Cutaneous Iontophoresis of Iloprost and Treprostinil in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: NaCl 0.9%
Drug: treprostinil
Drug: iloprost

First Posted Date: 2010-03-08

Last Posted Date: 2011-10-06

Lead Sponsor: University Hospital, Grenoble

Target Recruit Count: 20

Registration Number: NCT01082484

Locations: 🇫🇷
Unité de Pharmacologie Clinique, Inserm CIC3, CHU Grenoble, Grenoble, France

A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension

Completed

Conditions: Pulmonary Hypertension
Pulmonary Arterial Hypertension
Portopulmonary Hypertension

Interventions: Drug: Treprostinil

First Posted Date: 2009-12-09

Last Posted Date: 2017-02-24

Lead Sponsor: United Therapeutics

Target Recruit Count: 13

Registration Number: NCT01028651

Locations: 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Emory Univeristy, Atlanta, Georgia, United States

and more 1 locations

Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension

Phase 2

Completed

Conditions: Interstitial Lung Disease
Idiopathic Pulmonary Fibrosis
Pulmonary Arterial Hypertension

Interventions: Drug: Treprostinil

First Posted Date: 2008-06-25

Last Posted Date: 2020-09-09

Lead Sponsor: Rajan Saggar

Target Recruit Count: 15

Registration Number: NCT00705133

Locations: 🇺🇸
David Geffen School of Medicine, UCLA, Los Angeles, California, United States

Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH

Phase 4

Terminated

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: treprostinil
Device: Crono Five ambulatory pump

First Posted Date: 2007-02-26

Last Posted Date: 2024-01-03

Lead Sponsor: United Therapeutics

Target Recruit Count: 8

Registration Number: NCT00439946

Locations: 🇺🇸
THE NEW YORK-PRESBYTERIAN HOSPITAL Weill Cornell Medical Center, New York, New York, United States
🇺🇸
University of California San Francisco (UCSF) Medical Center, San Francisco, California, United States
🇺🇸
Integris Baptist Medical Center, Oklahoma City, Oklahoma, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy